ASEAN KEY DESTINATIONS
UCB and Biogen Idec Enter Agreements to Commercialize
Multiple Sclerosis and Hemophilia Therapies in Asia
Relationship Leverages UCB’s Expertise and Presence in Asia to Bring Biogen Idec’s Innovative Therapies to Patients in New Markets
Bangkok, Thailand - 10 February 2014: UCB and Biogen Idec today announced that they have signed an exclusive agreement granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, China, Singapore, Malaysia and Taiwan, and both develop and commercialize products in Thailand.
As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis therapies and investigational candidates, including TECFIDERA?, AVONEX?, TYSABRI? and FAMPYRA?. The relationship also includes ELOCTATE? and ALPROLIX?, Biogen Idec’s investigational long-acting recombinant-based treatments for hemophilia A and B, respectively.
“Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible,” said Carlos Dourado, Senior Vice President, Emerging Markets at Biogen Idec. “By leveraging UCB’s extensive resources, expertise and infrastructure in Asia, we are able to grow our footprint in critical Asian markets, get our therapies to patients as quickly as possible and create a foundation for further commercial success in this region.”
Mohamed Chaoui, Head of Asia Pacific at UCB, said: “As a patient centric biopharmaceutical company, UCB is delighted to work with Biogen Idec on delivering some of the most important breakthrough products in the treatment of multiple sclerosis and hemophilia to patients in Asia. This partnership is a strong complement in our goal to offer innovative specialty care therapeutic options to patients suffering from severe diseases. It further supports our strategic goal to strengthen our leadership and expertise in biologics in both neurology and immunology in Thailand and the Asian region.
Mr. Chaoui added, “We are committed to broadening and deepening our presence in Asia and offering patients and healthcare providers around the Asian region access to new and innovative treatment options. This agreement is also an important step for our specialty focused expansion in Thailand. It will help drive our business growth in other Southeast Asian markets, which is one of UCB’s top strategic priorities.”
In Thailand, UCB intends to bring these medicines to the market from 2014 onwards, pending regulatory approval. The offerings are complementary to UCB’s existing CNS portfolio and will enable the company to rapidly increase its critical mass in Thailand, reinforcing its strategic presence in both public and private hospitals and specialist clinics that have the potential to leverage UCB’s broader range of innovative solutions. Further, the launch-ready offerings will accelerate UCB’s expansion into Thailand, which the company has identified as a strategic growth priority.
Letters that do not contain full contact information cannot be published.
Letters become the property of AseanAffairs and may be republished in any format.
They typically run 150 words or less and may be edited
submit your comment in the box below